IAP7 Rec'd PCT/PTO 15 SEP 2006

Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 58086-235410 DESIGNATED/ELECTED OFFICE (DO/EO/US) (CFR 1.5) NOT YET ASSIGN **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/US2005/008621 14 March 2005 15 March 2004 TITLE OF INVENTION SPLIT ENZYME LINKED IMMUNOSORBENT AND NUCLEIC ACID ASSAYS APPLICANT(S) FOR DO/EO/US Shimon Weiss et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must 3. include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). 5. X A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). C. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 6. is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. х An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. 14. Х

A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.

A second copy of the published International Application under 35 U.S.C. 154(d)(4).

15.

16.


17.

18.

19.

A substitute specification.

A power of attorney and/or change of address letter.



PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Tracellar of Commence

			= 0	are required to respond to INTERNATIONAL APPLI			ATTORNEY'S DO			
U.S. APPLICATION NO. (HODING SET 7 CFR 7) INTERNATIONAL APPLICATION NO. PCT/US2005/008621				5/008621	58086-235410					
20. x Other items or information: Return Receipt Postcard; PCT/IB/304 PCT/IB/308 (First Notice); PCT/IB/308 (Second and Supplementary Notice) and Submission of Formal Drawings, Figs. 1-18 (18 sheets)										
The following fees have been submitted							CALCULATIO	Ne l	PTO USEONLY	
21. x Basic national fee (37 CFR 1.492(a))						\$ 300.	$\overline{}$	FIO OSCONCI		
22. x Examination fee (37 CFR 1.492(c))										
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0 All other situations \$200							\$ 200.	00		
23. X Search fee (37 CFR 1.492(b))										
If the written opinion of the ISA/US or the international preliminary examination report prepared by										
IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)										
International Searching Authority								00		
previously communicated to the US by the IB									:	
TOTAL OF 21, 22 and 23 =						\$ 1000.	00			
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets	Extra Sh	eets Number of each additional 50 or fraction RATE thereof (round up to a whole number)				RATE				
- 100 =	- 100 = /50 =			x \$250.00	\$!			
Surcharge of \$130 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).							\$			
		BER FILED NUMBER EXTRA RATE								
				×						
Independent claims 4 - 3 =		• •	1 ×		200.	00				
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + TOTAL OF ABOVE CALCULATIONS =							\$ 1200.			
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.							\$ 1200.00 600.00			
SUBTOTAL =							\$ 600.	00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).							\$			
TOTAL NATIONAL FEE =							\$ 600.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property										
\$										
TOTAL FEES ENCLOSED =						\$ 600.00				
							Amount to be refunded:	\$		
							Amount to be charged	\$	600.00	

10/593059

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE at to a collection of information unless it displays a valid OMB control number.

Officer the Paperwork Reduction Act of 1995, no persons are required to respond to a conec	aut of information difficas it displays a valid OMD control floribor.								
a. A check in the amount of \$ to cover the above	stees is analysed								
b. x Please charge my Deposit Account No. 22-0261 in the amou									
A duplicate copy of this sheet is enclosed.	hit Dani								
C. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 22-0261 . A duplicate copy of this sheet is enclosed.									
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038									
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed an granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:	SIGNATURE 9/15/06								
	Michael A. Gollin								
CUSTOMER NUMBER: 26694									
-	31,957 REGISTRATION NUMBER								

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Shimon WEISS et al.

Art Unit: Not Yet Assigned

Appl. No. Not Yet Assigned

Filed: Concurrently Herewith

Examiner: Not Yet Assigned

Confirmation No. Not Yet Assigned

Committee 1 to 1 to 1 to 1 to 1 to 1 to 1

Atty. Docket No. 58086- 235410

(formerly 018.0068)

For: SPLIT ENZYME LINKED

IMMUNOSORBENT AND NUCLEIC ACID ASSAYS Customer No.

26694

26694

PATENT TRADEMARK OFFICE

Submission Of Formal Drawings

Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith are eighteen (18) sheets of formal drawing containing Figures

1 through 18.

Date: 9/15/06

Respectfully submitted,

Michael A. Gollin Registration No. 31,957

VENABLE LLP P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

779813